AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Its pipeline centers on Ampligen® (rintatolimod), a nucleic-acid based immune modulator studied across indications including ME/CFS and immuno-oncology, and it also has an FDA-approved interferon product, Alferon N Injection. The company’s commercialization approach relies heavily on partnering—licensing, collaborations, and potential joint ventures—to obtain regulatory approvals and build commercial reach in specific territories. AIM currently generates only limited revenue (e.g., via an Ampligen cost recovery program) and positions partnerships and external funding as key enablers of development and commercialization.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueR&D and clinical development of Ampligen across ME/CFS, oncology and viral-disease applications.
Territory-based licensing/collaboration/joint-venture efforts to obtain approvals and commercialize products.
Limited patient access programs where participants support costs, producing small, variable revenue.
FDA-approved natural interferon product with commercialization dependent on partners and market access.
Customers
AIM’s near-term customers are a mix of (1) patients and clinical sites participating in access programs that support the cost of Ampligen supply, and (2) research institutions receiving product for antiviral research. A second, strategically critical “customer” group is potential pharmaceutical partners that can fund development, run registration programs, and commercialize Ampligen in specific territories. In Argentina, the company has worked through a distributor/partner model (GP Pharm/Filaxis) aimed at regulatory approval and commercialization for severe CFS, with exploration of oncology use cases such as pancreatic cancer. Because AIM does not currently generate material operating revenues, partner selection and deal terms (milestones, supply, territory rights) are central to how demand ultimately converts into revenue.
License or co-develop Ampligen (and potentially Alferon) to fund trials, secure approvals, and commercialize in defined territories.
Access Ampligen for severe disease settings (e.g., ME/CFS) with participation levels driving small, fluctuating revenue.
Obtain Ampligen supply for preclinical/clinical research (e.g., antiviral studies) to generate data supporting future development.
Distribute and commercialize Ampligen locally (historically Argentina via GP Pharm/Filaxis) subject to regulatory approvals and contract renewals.
Strategy
AIM’s strategy emphasizes finding senior co-development partners with the capital and expertise to run clinical programs, obtain regulatory approvals, and commercialize Ampligen across multiple indications and geographies. The company has used a partner/distributor model in Argentina and indicates openness to extending or replacing that partner to maintain momentum and broaden indications (including oncology such as pancreatic cancer). AIM also seeks to strengthen its intellectual property and manufacturing readiness for Ampligen, including patent filings related to coronavirus applications and a high-volume manufacturing process, and it has engaged external parties for clinical and regulatory support (e.g., a CRO). Corporate actions such as the 100-to-1 reverse stock split were undertaken to regain NYSE American compliance, supporting continued access to capital markets, which management indicates is necessary given limited operating revenue.
AIM indicates it lacks adequate funds to independently fund trials and commercialization.
Argentina is a concrete example of partner-led regulatory/commercial execution and could extend to other countries.
Clinical and preclinical data are key to attracting partners and enabling regulatory pathways in new indications.
Commercial viability depends on defensible IP and reliable, higher-volume supply capabilities.
Geography
AIM is headquartered in Ocala, Florida and operates primarily as a U.S.-based R&D organization while pursuing international commercialization through territorial partners. The most explicit non-U.S. commercial footprint discussed is Argentina, where a partner (GP Pharm/Filaxis) has been responsible for regulatory approval and commercialization efforts for Ampligen in severe CFS, with local regulatory authorization extended through 2026. The company also references a strategy to make Ampligen available worldwide via licensing/collaborations/joint ventures, implying a partner-led expansion model rather than building its own global sales infrastructure. Geography matters mainly through regulatory pathways, partner execution in each territory, and the ability to secure manufacturing and supply arrangements that can serve multiple regions.
Risks
AIM faces high development and financing risk because it reports no material operating revenues and states it does not have adequate funds to meet anticipated cash needs and fund current clinical trials. Clinical and regulatory risk is significant: Ampligen’s broader approvals depend on time-consuming preclinical and clinical work, and negative or inconclusive results can force additional studies and delays. The partner-led model introduces counterparty and execution risk, illustrated by the Argentina arrangement where Alferon efforts were discontinued by the partner and the company is negotiating an extension while also considering a new partner. Like other small biopharma companies, AIM is exposed to manufacturing/supply chain risk for specialized biologic production, IP protection risk, and market adoption risk if competing therapies or standards of care evolve faster than its development timelines.
The company states it does not have adequate funds to meet anticipated cash needs and does not generate material revenues.
Exposure: Ongoing R&D and trial commitments; need for additional funding
Strategy relies on licensing/collaborations/JVs; partner priorities can change and agreements may not be renewed.
Exposure: Argentina agreement extension discussions; partner discontinued Alferon effort
Reported Ampligen cost recovery revenue fluctuates with patient participation and is not a stable commercial base.
Exposure: Quarter-to-quarter variability in reported revenue
Accounting
Judgemental itemsRevenue is small and participation-driven, affecting comparability across quarters.
Impact: Quarterly revenue volatility and limited visibility into run-rate demand
Warrant valuation gains/losses can be large and non-cash, distorting net loss trends.
Impact: Material swings in other income/expense and net loss
Investment revaluations/realizations can move earnings independently of operating progress.
Impact: Non-operating volatility in reported results
Similar listed companies
Publicly listed companies with a comparable business focus.
Iovance Biotherapeutics, Inc
IOVA · Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Immunic, Inc
IMUX · Pharmaceutical Preparations
Alumis Inc
ALMS · Pharmaceutical Preparations
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026